Connor Clark & Lunn Investment Management Ltd. Purchases 43,525 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Key Points

• Connor Clark & Lunn Investment Management Ltd. increased its stake in Hims & Hers Health by 3.7%, acquiring an additional 43,525 shares, bringing their total holdings to approximately 1,216,499 shares valued at $35.9 million.
• Hims & Hers Health reported $0.17 earnings per share for the last quarter, missing analyst expectations by $0.01, even as revenue grew by 72.6% year-over-year to reach $544.83 million.
• Insider transactions included significant share sales, with CEO Andrew Dudum selling 128,127 shares and insider Patrick Harrison Carroll selling 60,000 shares in August, totaling approximately $10.5 million in value.

Connor Clark & Lunn Investment Management Ltd. increased its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 3.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,216,499 shares of the company's stock after purchasing an additional 43,525 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.54% of Hims & Hers Health worth $35,948,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of HIMS. UMB Bank n.a. raised its position in Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after buying an additional 933 shares during the last quarter. Larson Financial Group LLC raised its position in Hims & Hers Health by 47.7% in the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock valued at $42,000 after buying an additional 458 shares during the last quarter. Fifth Third Bancorp raised its position in Hims & Hers Health by 165.4% in the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock valued at $46,000 after buying an additional 961 shares during the last quarter. Tsfg LLC purchased a new stake in Hims & Hers Health in the 1st quarter valued at $46,000. Finally, N.E.W. Advisory Services LLC purchased a new stake in Hims & Hers Health in the 1st quarter valued at $49,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Trading Up 1.6%

Shares of HIMS opened at $51.87 on Friday. The business has a 50-day moving average of $53.66 and a 200 day moving average of $45.05. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The firm has a market cap of $11.61 billion, a P/E ratio of 64.84, a price-to-earnings-growth ratio of 3.29 and a beta of 2.08. The company has a debt-to-equity ratio of 1.72, a quick ratio of 1.32 and a current ratio of 4.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%. The firm had revenue of $544.83 million during the quarter, compared to analysts' expectations of $550.06 million. During the same period last year, the business posted $0.06 EPS. The company's revenue was up 72.6% compared to the same quarter last year. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Bank of America increased their price target on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a research report on Tuesday, April 29th. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their target price for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Morgan Stanley reiterated an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $39.83.

Insider Buying and Selling

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the completion of the transaction, the insider owned 169,940 shares of the company's stock, valued at $9,105,385.20. The trade was a 26.09% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $56.76, for a total value of $7,272,488.52. Following the transaction, the chief executive officer directly owned 160,215 shares of the company's stock, valued at $9,093,803.40. The trade was a 44.44% decrease in their position. The disclosure for this sale can be found here. Insiders sold 797,704 shares of company stock worth $43,858,835 over the last quarter. 13.71% of the stock is owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.